An Open-label, Single-dose Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects
Latest Information Update: 30 Nov 2021
At a glance
- Drugs ACT 1014 6470 (Primary)
- Indications Immunological disorders
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 26 Nov 2021 Status changed from recruiting to completed.
- 30 Jun 2021 Status changed from not yet recruiting to recruiting.
- 27 May 2021 New trial record